Filana Therapeutics (FLNA) EBT (2010 - 2026)

Filana Therapeutics has reported EBT for 17 years, with the latest figure at -$8.8 million in Q2 2026.

• On a quarterly basis, EBT rose 80.13% year-over-year to -$8.8 million in Q2 2026; TTM through Jun 2026 was -$43.0 million, a 65.28% increase from a year earlier, with the FY2025 full-year figure at -$91.1 million, up 32.19% from the prior year.
• EBT was -$8.8 million for Q2 2026 at Filana Therapeutics, up from -$10.6 million in the prior quarter.
• The five-year high for EBT was -$8.8 million in Q2 2026, with the low at -$59.3 million in Q2 2024.
• Average EBT over 5 years is -$23.5 million, with a median of -$21.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: EBT sank 413.33% in 2022, then surged 80.13% in 2026.
• Over 5 years, EBT stood at -$19.8 million in 2022, then decreased by 8.53% to -$21.5 million in 2023, then slipped by 29.45% to -$27.8 million in 2024, then jumped by 54.34% to -$12.7 million in 2025, then surged by 30.68% to -$8.8 million in 2026.
• The last three EBT figures came in at -$8.8 million (Q2 2026), -$10.6 million (Q1 2026), and -$12.7 million (Q4 2025), per Business Quant data.